Ameriprise’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$81.4M Sell
532,554
-37,168
-7% -$5.7M 0.02% 638
2025
Q4
$78.5M Sell
569,722
-14,931
-3% -$1.96M 0.02% 651
2025
Q3
$75M Sell
584,653
-46,478
-7% -$5.67M 0.02% 682
2025
Q2
$76.4M Buy
631,131
+244,037
+63% +$27.5M 0.02% 666
2025
Q1
$43.3M Buy
387,094
+36,131
+10% +$3.85M 0.01% 912
2024
Q4
$34.1M Sell
350,963
-73,865
-17% -$7.88M 0.01% 1047
2024
Q3
$48.9M Sell
424,828
-22,846
-5% -$2.59M 0.01% 858
2024
Q2
$47.7M Buy
447,674
+18,132
+4% +$1.82M 0.01% 822
2024
Q1
$41.6M Buy
429,542
+64,829
+18% +$6.65M 0.01% 895
2023
Q4
$36.8M Sell
364,713
-12,336
-3% -$1.19M 0.01% 920
2023
Q3
$38.4M Sell
377,049
-46,338
-11% -$4.7M 0.01% 870
2023
Q2
$42.8M Buy
423,387
+9,632
+2% +$963K 0.01% 830
2023
Q1
$38.1M Sell
413,755
-154,542
-27% -$13.5M 0.01% 889
2022
Q4
$51.6M Sell
568,297
-76,390
-12% -$6.43M 0.02% 716
2022
Q3
$49M Sell
644,687
-66,093
-9% -$5.48M 0.02% 712
2022
Q2
$60.1M Sell
710,780
-766,267
-52% -$67.2M 0.02% 649
2022
Q1
$130M Buy
1,477,047
+129,010
+10% +$11.2M 0.04% 443
2021
Q4
$118M Sell
1,348,037
-66,951
-5% -$5.56M 0.03% 507
2021
Q3
$116M Sell
1,414,988
-313,799
-18% -$28.2M 0.04% 475
2021
Q2
$158M Buy
1,728,787
+3,619
+0.2% +$322K 0.05% 387
2021
Q1
$147M Sell
1,725,168
-27,982
-2% -$2.51M 0.05% 372
2020
Q4
$166M Buy
1,753,150
+637,848
+57% +$55.7M 0.06% 332
2020
Q3
$97.1M Sell
1,115,302
-53,513
-5% -$4.64M 0.04% 429
2020
Q2
$102M Sell
1,168,815
-38,000
-3% -$3.28M 0.04% 386
2020
Q1
$99.4M Sell
1,206,815
-3,559
-0.3% -$318K 0.05% 332
2019
Q4
$115M Buy
1,210,374
+183,560
+18% +$16.5M 0.05% 367
2019
Q3
$89.2M Sell
1,026,814
-28,301
-3% -$2.54M 0.04% 444
2019
Q2
$96.3M Sell
1,055,115
-125,461
-11% -$10.6M 0.04% 432
2019
Q1
$102M Buy
1,180,576
+12,467
+1% +$1M 0.05% 404
2018
Q4
$89.8M Buy
1,168,109
+73,767
+7% +$5.74M 0.04% 404
2018
Q3
$106M Buy
1,094,342
+58,720
+6% +$4.34M 0.04% 444
2018
Q2
$70.1M Buy
1,035,622
+26,313
+3% +$1.82M 0.03% 521
2018
Q1
$73.2M Sell
1,009,309
-59,937
-6% -$4.56M 0.03% 492
2017
Q4
$80.4M Sell
1,069,246
-24,571
-2% -$1.85M 0.04% 427
2017
Q3
$84.1M Sell
1,093,817
-24,512
-2% -$1.85M 0.04% 407
2017
Q2
$83.6M Sell
1,118,329
-229,705
-17% -$16.3M 0.04% 403
2017
Q1
$89.8M Sell
1,348,034
-215,474
-14% -$14.4M 0.05% 370
2016
Q4
$102M Sell
1,563,508
-40,450
-3% -$2.62M 0.06% 341
2016
Q3
$113M Sell
1,603,958
-25,287
-2% -$1.84M 0.06% 313
2016
Q2
$120M Buy
1,629,245
+31,490
+2% +$2.18M 0.07% 270
2016
Q1
$104M Buy
1,597,755
+128,929
+9% +$8.77M 0.06% 296
2015
Q4
$113M Sell
1,468,826
-28,112
-2% -$2.23M 0.07% 276
2015
Q3
$123M Sell
1,496,938
-412,005
-22% -$36.7M 0.08% 250
2015
Q2
$168M Buy
1,908,943
+44,185
+2% +$4.05M 0.1% 214
2015
Q1
$165M Buy
1,864,758
+35,647
+2% +$3.16M 0.09% 221
2014
Q4
$152M Buy
1,829,111
+25,253
+1% +$2.09M 0.09% 236
2014
Q3
$152M Buy
1,803,858
+15,411
+0.9% +$1.25M 0.09% 234
2014
Q2
$145M Sell
1,788,447
-5,369
-0.3% -$422K 0.09% 236
2014
Q1
$137M Buy
1,793,816
+405,367
+29% +$29.5M 0.08% 248
2013
Q4
$100M Buy
1,388,449
+143,539
+12% +$9.98M 0.06% 320
2013
Q3
$85.6M Sell
1,244,910
-158,265
-11% -$10.5M 0.06% 355
2013
Q2
$88.9M Buy
+1,403,175
New +$91.3M 0.06% 347

Other funds holding NVS

Ameriprise's NVS Position: Q1 2026 in Review

Ameriprise reduced its Novartis (NVS) stake by 6.5% in Q1 2026, selling an estimated $5.7M and leaving 532,554 shares worth $81.4M. The position accounts for 0.02% of the portfolio, ranked #638.

Ameriprise first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $168M in Q2 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Ameriprise held 532,554 shares of Novartis worth $81.4M as of Q1 2026.
  • Ameriprise sold 37,168 Novartis shares in Q1 2026, an estimated $5.7M.
  • Novartis made up 0.02% of Ameriprise's portfolio in Q1 2026, its #638 holding.
  • Ameriprise first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Novartis position peaked at $168M in Q2 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.